TALLC to introduce TA-A001, our proprietary CB2R agonist, and the enabling effects of SmartCelle ocular delivery technology at the Ophthalmology Innovation Summit: Drug Delivery Showcase.
TALLC and IACTA to present at the H.C. Wainwright Bioconnect Conference: January 10-13, 2022
https://lnkd.in/g5ZhR2Yn
TALLC will present details of the SmartCelle insoluble drug delivery platform for ocular, parenteral and oral delivery and an update on t…https://lnkd.in/gAwAqwnQ
